论文部分内容阅读
目的观察EPOCH方案治疗非霍奇金淋巴瘤的临床疗效和毒副反应。方法经病理确诊为非霍奇金淋巴瘤35例,采用EP-OCH方案化疗,VP-16 50 mg/m2,ADM 10 mg/m2或E-ADM 12 mg/m2,VCR 0.4 mg/m2,溶解于生理盐水500 mL持续静滴24 h,第1~4天;CTX 750 mg/m2,静脉推注,第6天;强地松60 mg/m2,口服,第1~6天,21 d为1周期。结果35例中CR/CRU 11例(31.4%),PR 17例(48.6%),总有效率80.0%,其中复治23例,CR/CRU 6例(26.1%),PR 11例(47.8%),总有效率73.9%。主要毒副反应为白细胞、血小板减少,其中Ⅲ~Ⅳ度发生率分别为34.2%(12/35)和42.9%(15/35),心房纤颤2.9%(1/35)。结论EPOCH方案是治疗非霍奇金淋巴瘤有效的治疗方案,耐受性较好,值得进一步研究。
Objective To observe the clinical efficacy and side effects of EPOCH regimen in the treatment of non-Hodgkin’s lymphoma. Methods Fifty-five non-Hodgkin’s lymphoma patients were diagnosed by EP-OCH regimen. VP-16 50 mg / m2, ADM 10 mg / m2 or E-ADM 12 mg / m2, VCR 0.4 mg / Intravenous injection of CTX 750 mg / m2 on day 6; prednisone 60 mg / m2 orally on days 1 to 6 and 21 d 1 cycle. Results Among the 35 cases, CR / CRU was found in 11 cases (31.4%) and PR (17 cases) in 17 cases (48.6%). The total effective rate was 80.0% ), The total effective rate of 73.9%. The main toxicities were leukopenia and thrombocytopenia. The incidence of grade Ⅲ-Ⅳ was 34.2% (12/35) and 42.9% (15/35) respectively, and atrial fibrillation was 2.9% (1/35). Conclusion EPOCH regimen is an effective treatment for non-Hodgkin’s lymphoma. It is well tolerated and deserves further study.